Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Multiple Sclerosis Excellence Forum

Multiple Sclerosis
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Lori Kostich, CCC-SLP, on Managing Dysphagia in Multiple Sclerosis
Podcasts
Lori Kostich, CCC-SLP, on Managing Dysphagia in Multiple Sclerosis
09/17/2020
In this podcast, Lori Kostich, CCC-SLP, from the Mandell Center for Multiple Sclerosis Treatment and Research, discusses how she identifies and manages dysphagia among her patients with multiple sclerosis, and when neurologists should refer...
In this podcast, Lori Kostich, CCC-SLP, from the Mandell Center for Multiple Sclerosis Treatment and Research, discusses how she identifies and manages dysphagia among her patients with multiple sclerosis, and when neurologists should refer...
In this podcast, Lori Kostich,...
09/17/2020
Neurology
4 Questions About Prodromal Multiple Sclerosis
Q&As
4 Questions About Prodromal Multiple Sclerosis
09/07/2020
Neurology Consultant spoke with Helen Tremlett, PhD, from the University of British Columbia, whose recent study adds to increasing evidence of a multiple sclerosis prodrome. Dr Tremlett discussed this topic during the Paty Lecture at the...
Neurology Consultant spoke with Helen Tremlett, PhD, from the University of British Columbia, whose recent study adds to increasing evidence of a multiple sclerosis prodrome. Dr Tremlett discussed this topic during the Paty Lecture at the...
Neurology Consultant spoke with...
09/07/2020
Neurology
Leigh Charvet, PhD, & Tehila Eilam-Stock, PhD, on Early Markers of Cognitive Involvement in MS
Podcasts
Leigh Charvet, PhD, & Tehila Eilam-Stock, PhD, on Early Markers of Cognitive Involvement in MS
09/03/2020
In this podcast, Dr Charvet and Dr Eilam-Stock discuss the findings from their study, which provided evidence of early neuropsychological markers of cognitive involvement among patients with multiple sclerosis.
In this podcast, Dr Charvet and Dr Eilam-Stock discuss the findings from their study, which provided evidence of early neuropsychological markers of cognitive involvement among patients with multiple sclerosis.
In this podcast, Dr Charvet and...
09/03/2020
Neurology
Patricia K. Coyle, MD, on Fluid and Neurophysiological Biomarkers for the Early Diagnosis of Progression of RRMS to SPMS
Podcasts
Patricia K. Coyle, MD, on Fluid and Neurophysiological Biomarkers for the Early Diagnosis of Progression of RRMS to SPMS
08/26/2020
She discusses the current state of evidence on the role of fluid and neurophysiological biomarkers in the early diagnosis of progression of relapsing-remitting MS to secondary progressive MS, and more.
She discusses the current state of evidence on the role of fluid and neurophysiological biomarkers in the early diagnosis of progression of relapsing-remitting MS to secondary progressive MS, and more.
She discusses the current state...
08/26/2020
Neurology
How I Practice Now: How the Pandemic Has Affected My MS Practice
Videos
How I Practice Now: How the Pandemic Has Affected My MS Practice
08/13/2020
Pavan Bhargava, MD, discusses how he and his colleagues are treating patients with multiple sclerosis via telemedicine amid the ongoing pandemic.
Pavan Bhargava, MD, discusses how he and his colleagues are treating patients with multiple sclerosis via telemedicine amid the ongoing pandemic.
Pavan Bhargava, MD, discusses...
08/13/2020
Neurology
John DeLuca, PhD, on Cognitive Rehabilitation Tools for Relapsing-Remitting MS
Podcasts
John DeLuca, PhD, on Cognitive Rehabilitation Tools for Relapsing-Remitting MS
07/27/2020
In this podcast, Dr DeLuca discusses the clinical course and prognosis of cognitive impairment in relapsing-remitting multiple sclerosis, as well as cognitive rehabilitation tools that are currently available and on the horizon.
In this podcast, Dr DeLuca discusses the clinical course and prognosis of cognitive impairment in relapsing-remitting multiple sclerosis, as well as cognitive rehabilitation tools that are currently available and on the horizon.
In this podcast, Dr DeLuca...
07/27/2020
Neurology
Mona Bostick, RDN, LDN, on Nutrition Care in Multiple Sclerosis
Podcasts
Mona Bostick, RDN, LDN, on Nutrition Care in Multiple Sclerosis
07/23/2020
Mona Bostick, RDN, LDN, discusses nutrition and the role of multidisciplinary nutrition care for patients with multiple sclerosis. She recently gave a talk on this topic at the 2020 CMSC Virtual Meeting.
Mona Bostick, RDN, LDN, discusses nutrition and the role of multidisciplinary nutrition care for patients with multiple sclerosis. She recently gave a talk on this topic at the 2020 CMSC Virtual Meeting.
Mona Bostick, RDN, LDN,...
07/23/2020
Neurology
Patricia K. Coyle, MD, on Progressive Multiple Sclerosis
Podcasts
Patricia K. Coyle, MD, on Progressive Multiple Sclerosis
07/23/2020
In this podcast, Dr Coyle reviews the diagnosis and clinical course of progressive multiple sclerosis (MS), pearls for distinguishing it from its differential diagnosis, and the importance of multidisciplinary care in the long-term management...
In this podcast, Dr Coyle reviews the diagnosis and clinical course of progressive multiple sclerosis (MS), pearls for distinguishing it from its differential diagnosis, and the importance of multidisciplinary care in the long-term management...
In this podcast, Dr Coyle...
07/23/2020
Neurology
ANA Investigates Cannabis and Cannabinoids for MS Symptoms
Podcasts
ANA Investigates Cannabis and Cannabinoids for MS Symptoms
07/20/2020
Michelle Cameron, MD, PT, talks about the federal and state legalities surrounding cannabinoid use, how cannabinoids go through the FDA approval process, and how cannabinoids can be used to treat symptoms of multiple sclerosis.
Michelle Cameron, MD, PT, talks about the federal and state legalities surrounding cannabinoid use, how cannabinoids go through the FDA approval process, and how cannabinoids can be used to treat symptoms of multiple sclerosis.
Michelle Cameron, MD, PT, talks...
07/20/2020
Neurology
Kristen Krysko, MD, on Newer vs Injectable Disease-Modifying Therapies for Initial Treatment of Pediatric MS
Videos
Kristen Krysko, MD, on Newer vs Injectable Disease-Modifying Therapies for Initial Treatment of Pediatric MS
06/01/2020
In this video, Dr Krysko discusses the findings from her study on the real-world effectiveness of newer vs injectable disease-modifying therapies among pediatric patients with multiple sclerosis.
In this video, Dr Krysko discusses the findings from her study on the real-world effectiveness of newer vs injectable disease-modifying therapies among pediatric patients with multiple sclerosis.
In this video, Dr Krysko...
06/01/2020
Neurology

Advertisement

Advertisement

News

neurologist and patient
New Study Brief
Study Emphasizes Importance of Appropriate Application of McDonald Criteria in PPMS Diagnoses
09/15/2023

Tom Valentino

Tom Valentino
A comprehensive approach to primary progressive multiple sclerosis (PPMS) diagnosis that includes correct application of the McDonald criteria in real-world settings can improve diagnostic accuracy.
A comprehensive approach to primary progressive multiple sclerosis (PPMS) diagnosis that includes correct application of the McDonald criteria in real-world settings can improve diagnostic accuracy.
A comprehensive approach to...
09/15/2023
Neurology
Fremanezumab Shows Positive Results for Pediatric Use in Phase 3 Trial
News
Fremanezumab Shows Positive Results for Pediatric Use in Phase 3 Trial
08/08/2024
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
In July, Teva announced positive...
08/08/2024
Neurology
brain waves
News
High-Dose Statins May Not Benefit Patients With Mild Ischemic Stroke
08/08/2024
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Compared with moderate-dose...
08/08/2024
Neurology
An illustration of a healthcare provider conducting a telehealth appointment
News
Teleneurology Visits Acceptable to Patients Across Neurologic Conditions
08/05/2024
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
Regardless of their neurologic...
08/05/2024
Neurology
The US Food and Drug Administration headquarters sign.
News
DMD Gene Therapy Indication Expanded to Include Boys 4 and Older
08/01/2024
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
The US FDA approved an...
08/01/2024
Neurology
A person walks down a boarded path with sunlight and trees in the background
News
Backward Walking Speed Reserve Reflects Disease Severity in Patients With MS
07/30/2024
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve,...
07/30/2024
Neurology
FDA Approves Efgartigimod Alfa/Hyaluronidase for CIDP Treatment
News
FDA Approves Efgartigimod Alfa/Hyaluronidase for CIDP Treatment
07/29/2024
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 
VYVGART Hytrulo (efgartigimod...
07/29/2024
Neurology
A middle-aged male running
News
Moderate Physical Activity May Mitigate ALS Risk for Male Patients
07/25/2024
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in...
07/25/2024
Neurology
Pitolisant Receives FDA Approval for Pediatric Patients With Narcolepsy
News
Pitolisant Receives FDA Approval for Pediatric Patients With Narcolepsy
07/23/2024
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
The US Food and Drug...
07/23/2024
Neurology
Chronic Loneliness Associated With Hiked Stroke Risk in Older Adults
News
Chronic Loneliness Associated With Hiked Stroke Risk in Older Adults
07/22/2024
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine. 
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine. 
Chronic loneliness was...
07/22/2024
Neurology
a hand breaks a wooden human figurine in half
News
Atogepant Reduces Migraine Days in Patients With Pain Medication Overuse
07/18/2024
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
The calcitonin gene-related...
07/18/2024
Neurology

Advertisement

Advertisement

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement